- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04475536
A Prospective Study, Single-arm, Multicentre, Observational to Evaluate Safety and Effectiveness of Stent Ultimaster Tansei Coronary Stent in Complex Coronary Lesions. (TANSEI)
April 25, 2023 updated by: Fundación EPIC
This prospective registry is intended to evaluate the safety and efficacy of the TANSEI stent.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This prospective registry is intended to analyze clinical outcomes in patients treated with TANSEI stent in patients with complex coronary lesions .
Study Type
Observational
Enrollment (Actual)
501
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: FUNDACION EPIC
- Phone Number: +34987876135
- Email: iepic@fundacionepic.org
Study Contact Backup
- Name: Bruno Garcia del Blanco, MD, PhD
- Phone Number: +34932746155
- Email: brunogb51@gmail.com
Study Locations
-
-
-
Albacete, Spain, 02006
- Hospital General Universitario
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Ciudad Real, Spain, 13005
- Hospital General Universitario De Ciudad Real
-
Coruña, Spain, 15006
- Hospital Universitario de A Coruna
-
Córdoba, Spain, 14004
- Hospital Universitario Reina Sofia
-
Gijón, Spain, 33394
- Hospital Universitario de Cabueñes
-
Huelva, Spain, 21005
- Hospital General Juan Ramon Jimenez
-
Las Palmas De Gran Canaria, Spain, 35010
- Hospital Universitario de Gran Canaria Dr. Negrin
-
León, Spain, 24001
- Hospital Universitario de Leon
-
Lugo, Spain, 27003
- Hospital Universitario Lucus Agusti
-
Majadahonda, Spain, 28222
- Hospital Universitario Puerta de Hierro
-
Murcia, Spain, 30120
- Hospital Clinico Universitario Virgen Arrixaca
-
Málaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdcilla
-
Valencia, Spain, 46010
- Hospital Clínico Universitario de Valencia
-
-
LA Coruña
-
Santiago De Compostela, LA Coruña, Spain, 15706
- Hospital Clinico Universitario de Santiago de Compostela
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with de novo native and complex coronary artery lesions, candidate to undergo revascularisation with a coronary device.
Description
Inclusion Criteria:
- Age> 18 years.
- With indication of percutaneous revascularization.
Complex coronary lesion defined as:
- Left main lesion AND/OR
- Lesion located at a major bifurcation (side branch >2mm) AND/OR
- Lesion located in a small vessel (<2.5 mm reference diameter by visual estimation) AND/OR
- Lesion length > 35 mm
- Informed consent signed.
Exclusion Criteria:
- Cardiogenic shock at the time of the PCI(Percutaneous Coronary Intervention).
- Life expectancy of the patient under 1 year.
- Patients included in other studies or clinical trials.
- Clinical decision that excludes the use of drug-eluting stents.
- Confirmed allergy to aspirin and / or thienopyridines.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Coronary Artery Disease (CAD)
|
stenting with the TANSEI sirolimus-eluting stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety.The composite of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).
Time Frame: 12 months
|
The composite of cardiac death, myocardial infarction (MI) and stent thrombosis (Academic Research Consortium definitive/probable).
|
12 months
|
Efficacy.The incidence of clinically driven target lesion revascularization.
Time Frame: 12 months
|
The incidence of clinically driven target lesion revascularization (TLR).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All death.
Time Frame: 12 months
|
All death.
|
12 months
|
Cardiac death.
Time Frame: 12 months
|
Cardiac death.
|
12 months
|
Target Vessel revascularization.
Time Frame: 12 months
|
Target Vessel revascularization.
|
12 months
|
Target lesion revascularization.
Time Frame: 12 months
|
Target lesion revascularization.
|
12 months
|
Stent thrombosis (ARC definite/probable).
Time Frame: 12 months
|
Stent thrombosis (ARC definite/probable).
|
12 months
|
Major bleeding event (BARC type 2-5).
Time Frame: 12 months
|
Major bleeding event (BARC type 2-5).
|
12 months
|
Stroke.
Time Frame: 12 months
|
Stroke.
|
12 months
|
Procedural success.
Time Frame: 12 months
|
Procedural success ( Residual stenosis <30% after implantation at the narrowest point of the treated vascular segment).
|
12 months
|
Rate of patients with DAPT
Time Frame: From 1 to 6 months
|
Rate of patients with DAPT
|
From 1 to 6 months
|
Rate of patients with DAPT
Time Frame: From 6 to 12 months
|
Rate of patients with DAPT
|
From 6 to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014 Aug 7;35(30):2021-31. doi: 10.1093/eurheartj/ehu210. Epub 2014 May 19.
- Orvin K, Carrie D, Richardt G, Desmet W, Assali A, Werner G, Ikari Y, Fujii K, Goicolea J, Dangoisse V, Manari A, Saito S, Wijns W, Kornowski R. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Interv. 2016 May;87(6):1092-100. doi: 10.1002/ccd.26150. Epub 2015 Aug 13.
- Lesiak M, Araszkiewicz A, Grajek S, Colombo A, Lalmand J, Carstensen S, Namiki A, Tobaru T, Merkely B, Moreno R, Barbato E, Wijns W, Saito S. Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. J Interv Cardiol. 2016 Feb;29(1):47-56. doi: 10.1111/joic.12262.
- Derimay F, Souteyrand G, Motreff P, Rioufol G, Finet G. Influence of platform design of six different drug-eluting stents in provisional coronary bifurcation stenting by rePOT sequence: a comparative bench analysis. EuroIntervention. 2017 Oct 13;13(9):e1092-e1095. doi: 10.4244/EIJ-D-16-00863.
- Chevalier B, Smits PC, Carrie D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamie D, Kraaijeveld AO, Hovasse T, Vlachojannis GJ. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months). Circ Cardiovasc Interv. 2017 Dec;10(12):e004801. doi: 10.1161/CIRCINTERVENTIONS.116.004801.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 21, 2020
Primary Completion (Anticipated)
May 1, 2023
Study Completion (Anticipated)
February 1, 2024
Study Registration Dates
First Submitted
July 16, 2020
First Submitted That Met QC Criteria
July 16, 2020
First Posted (Actual)
July 17, 2020
Study Record Updates
Last Update Posted (Actual)
April 26, 2023
Last Update Submitted That Met QC Criteria
April 25, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC08-TANSEI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on TANSEI stent
-
Duk-Woo Park, MDCardioVascular Research Foundation, KoreaRecruitingCoronary Artery DiseaseKorea, Republic of
-
Pieter C.SmitsSahajanand Medical Technologies LimitedCompletedCardiac Disease | PCI | High Bleeding RiskNetherlands
-
Instituto Nacional de Cardiologia Ignacio ChavezRecruitingCoronary Artery Disease | Percutaneous Coronary Intervention | High Bleeding RiskMexico
-
Zhujiang HospitalNanfang Hospital of Southern Medical University; Guangdong Provincial People...UnknownTrials of Clinical Curative Effect, Follow-up Study and Hemodynamics of Treatment of IA Using StentsTreatment Outcome by Stent-assisted EmbolizationChina
-
Royal Sussex County HospitalTerumo CorporationCompletedCoronary DiseaseUnited Kingdom
-
Southeast University, ChinaUnknownEsophageal CancerChina
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedVaginal StrictureUnited States
-
Merit Medical Systems, Inc.CompletedVenous Stenosis | Venous OcclusionUnited Kingdom, Greece
-
UMC UtrechtUnknownAcute Coronary Syndrome | Stable Angina PectorisNetherlands, Luxembourg
-
Chang Gung Memorial HospitalNot yet recruitingVascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation LesionsCoronary Artery DiseaseTaiwan